- Home
- KFFB vs INAB Comparison
KFFB vs INAB Comparison
Compare KFFB & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KFFB | INAB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 10.6M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KFFB | INAB |
|---|---|---|
| Price | $4.38 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | 7.7K | ★ 653.6K |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $9,467,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $67.62 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $1.96 | $1.17 |
| 52 Week High | $4.97 | $12.53 |
Technical Indicators
Market Signals| Indicator | KFFB | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 66.34 |
| Support Level | $4.21 | $1.17 |
| Resistance Level | $4.89 | $1.87 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 36.92 | 97.20 |
Price Performance
Historical ComparisonAbout KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.